Moleculin Receives FDA Allowance to Begin a Phase 1 Study of WP1122 for the Treatment of Glioblastoma Multiforme
New US IND enables parallel development of WP1122 as a cancer therapy HOUSTON, Dec. 1, 2021 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly...
Moleculin Biotech, Inc to Present at the Virtual Investor Roundtable Event
- Live moderated video webcast discussion among members of management and Thought Leader Sant P. Chawla, MD on Thursday, November 18th at 11:00 AM ET -HOUSTON, Nov. 12, 2021 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage...
Moleculin Reports Third Quarter 2021 Financial Results and Provides Programs Update
- Up to six clinical trials expected to be underway or with regulatory clearance by the end of 2021 -- Preliminary clinical activity for Annamycin seen in interim results from its US Phase 1b/2 clinical trial for the treatment of soft tissue sarcoma (STS) lung...
Moleculin Receives Authorization from the Medicines and Healthcare Products Regulatory Agency (MHRA) to Commence Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19
- First-in-human Phase 1a study to evaluate safety and pharmacokinetics of WP1122 in healthy volunteers and establish maximum tolerated dose expected to commence in 4th Quarter 2021 -- Based on previously announced preclinical data demonstrating its antiviral...
Moleculin Announces Interim Data in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases
- Preliminary data from two cohorts evaluating Annamycin for the treatment of soft tissue sarcoma lung metastases currently demonstrate 80% clinical activity, defined as stable disease and/or better- Patient enrollment and dosing ongoing; no dose-limiting toxicity...
Moleculin to Present at the 2021 Cantor Virtual Global Healthcare Conference
- Live webcast presentation on Monday, September 27th at 8:40 AM ETHOUSTON, Sept. 27, 2021 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly...
Moleculin to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
- Live webcast presentation on Monday, September 20th at 4:35 PM ET HOUSTON, Sept. 17, 2021 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly...
Moleculin to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
HOUSTON, Sept. 8, 2021 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp, President...
Moleculin Reports Second Quarter 2021 Financial Results and Provides Programs Update
- Continued execution of multiple ongoing clinical studies for the treatment of highly resistant tumors and viruses -- Key clinical and regulatory milestones throughout next 18 months including topline results from the ongoing Phase 1/2 study of Annamycin for...
Moleculin Receives Approval to Extend Dose Escalation in Phase 1/2 European Clinical Trial Evaluating Annamycin for the Treatment of Acute Myeloid Leukemia
- Protocol amendment allows for change in dose limiting toxicity (DLT) criteria for future enrolled subjects- Demonstrated efficacy in 240 mg/m² cohort with Annamycin- Annamycin has demonstrated little to no cardiotoxicity, avoids multidrug resistance, has been...